Strata Critical Medical, Inc.
SRTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | -0.05 | 0.28 | 0.61 |
| FCF Yield | -10.78% | -13.28% | -14.85% | -2.25% |
| EV / EBITDA | -11.45 | -4.20 | -3.29 | -30.95 |
| Quality | ||||
| ROIC | -14.17% | -25.12% | -17.25% | -6.83% |
| Gross Margin | 23.69% | 18.71% | 15.24% | 20.82% |
| Cash Conversion Ratio | 0.09 | 0.58 | 1.36 | 0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.39% | 64.57% | 84.06% | 17.44% |
| Free Cash Flow Growth | -3.06% | 8.99% | -130.63% | -46.64% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.05 | 0.36 | 0.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 109.89 | 45.83 |
| Cash Conversion Cycle | 31.69 | 34.05 | -18.24 | 7.48 |